Jasper Therapeutics Inc (JSPR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jasper Therapeutics Inc (JSPR) has a cash flow conversion efficiency ratio of -4.279x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.55 Million) by net assets ($3.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see JSPR market cap for the company's overall valuation and market capitalisation.
Jasper Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Jasper Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Jasper Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jasper Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Jasper Therapeutics Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pergamon Status Dis Ticaret AS
IS:PSDTC
|
-0.002x |
|
HiTi Digital Inc
TW:3494
|
0.088x |
|
Uniserve Communications Corp
V:USS
|
-0.071x |
|
Invoicery Group AB
ST:FRILAN
|
-0.429x |
|
BRIDGETEC Corp
KQ:064480
|
-0.028x |
|
Garden Stage Limited Ordinary Shares
NASDAQ:GSIW
|
-0.034x |
|
Philippos Nakas S.A
AT:NAKAS
|
0.086x |
|
TAG Oil Ltd.
V:TAO
|
-0.021x |
Annual Cash Flow Conversion Efficiency for Jasper Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Jasper Therapeutics Inc from 2019 to 2025. View JSPR share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.15 Million | $-77.16 Million | -18.589x | -1731.30% |
| 2024-12-31 | $61.67 Million | $-62.60 Million | -1.015x | -52.92% |
| 2023-12-31 | $78.44 Million | $-52.07 Million | -0.664x | +47.91% |
| 2022-12-31 | $35.99 Million | $-45.86 Million | -1.274x | -163.02% |
| 2021-12-31 | $69.52 Million | $-33.68 Million | -0.484x | -193.17% |
| 2020-12-31 | $-35.13 Million | $-18.27 Million | 0.520x | +657.27% |
| 2019-12-31 | $21.10 Million | $-1.97 Million | -0.093x | -- |
About Jasper Therapeutics Inc
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commerci… Read more